46
Participants
Start Date
September 30, 1999
Primary Completion Date
January 31, 2003
Study Completion Date
April 30, 2009
Taxotere
Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Cisplatin
Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
CPT-11
Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Brigham and Women's Hospital
OTHER
Massachusetts General Hospital
OTHER
Dana-Farber Cancer Institute
OTHER